Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial
Tóm tắt
The ReCharge Trial demonstrated that a vagal blocking device (vBloc) is a safe and effective treatment for moderate to severe obesity. This report summarizes 24-month outcomes. Participants with body mass index (BMI) 40 to 45 kg/m2, or 35 to 40 kg/m2 with at least one comorbid condition were randomized to either vBloc therapy or sham intervention for 12 months. After 12 months, participants randomized to vBloc continued open-label vBloc therapy and are the focus of this report. Weight loss, adverse events, comorbid risk factors, and quality of life (QOL) will be assessed for 5 years. At 24 months, 123 (76 %) vBloc participants remained in the trial. Participants who presented at 24 months (n = 103) had a mean excess weight loss (EWL) of 21 % (8 % total weight loss [TWL]); 58 % of participants had ≥5 % TWL and 34 % had ≥10 % TWL. Among the subset of participants with abnormal preoperative values, significant improvements were observed in mean LDL (−16 mg/dL) and HDL cholesterol (+4 mg/dL), triglycerides (−46 mg/dL), HbA1c (−0.3 %), and systolic (−11 mmHg) and diastolic blood pressures (−10 mmHg). QOL measures were significantly improved. Heartburn/dyspepsia and implant site pain were the most frequently reported adverse events. The primary related serious adverse event rate was 4.3 %. vBloc therapy continues to result in medically meaningful weight loss with a favorable safety profile through 2 years.
https://clinicaltrials.gov/ct2/show/NCT01327976
Tài liệu tham khảo
Kral JG, Gortz L, Hermansson G, Wallin GS. Gastropalsty for obesity: long-term weight loss improved by vagotomy. World J Surg. 1993;17:75–9.
Smith DK, Sarfeh J, Howard L. Truncal vagotomy in hypothalamic obesity. Lancet. 1983;1:1330–1.
Ikramuddin S, Blackstone RP, Brancatisano A, Toouli J, Shah SN, Wolfe BM, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA. 2014;312(9):915–22. doi:10.1001/jama.2014.10540.
Shikora S, Toouli J, Herrera MF, Kulseng B, Zulewski H, Brancatisano R, et al. Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus. J Obes. 2013;2013:245683. doi:10.1155/2013/245683.
Sarr MG, Billington CJ, Brancatisano R, Brancatisano A, Toouli J, Kow L, et al. The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity. Obes Surg. 2012;22(11):1771–82. doi:10.1007/s11695-012-0751-8.
Shikora SA, Wolfe BM, Apovian CM, Anvari M, Sarwer DB, Gibbons RD, et al. Sustained weight loss with vagal nerve blockade but not with sham: 18-month results of the ReCharge trial. J Obes. 2015;2015:365604. doi:10.1155/2015/365604.
Camilleri M, Toouli J, Herrera MF, Kulseng B, Kow L, Pantoja JP, et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. Surgery. 2008;143(6):723–31. doi:10.1016/j.surg.2008.03.015.
Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obesity Research. 2001;9(2):102–11. doi:10.1038/oby.2001.13.
Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71–83.
American Diabetes A. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl):S8–S16. doi:10.2337/dc15-S005.
Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–8. doi:10.1161/01.CIR.0000111245.75752.C6.
Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwin JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. NEJM. 2012;366:1567–76.
Schauer PR, Bhatt DL, Kirwin JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes—3-year outcomes. NEJM. 2014. doi:10.1056/ NEJMoa1401329.
Gill RS, Majumdar SR, Rueda-Clausen CF, Apte S, Birch DW, Karmali S, et al. Comparative effectiveness and safety of gastric bypass, sleeve gastrectomy and adjustable gastric banding in a population-based bariatric program: prospective cohort study. Can J Surg. 2016. doi:10.1503/cjs.013315.